You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)治療糖尿病藥物獲國家藥監局頒發藥品註冊證書
阿思達克 03-10 12:17
中國生物製藥(01177.HK)公布,集團開發的糖尿病治療藥物「磷酸西格列汀片」(商標名:品定)(產品規格:50mg及100mg)獲得中國國家藥監局頒發藥品註冊證書,且視同通過仿製藥質量和療效一致性評價。 西格列汀是全球首個獲批的口服二(月太)基(月太)(酉每)-4(DPP-4)抑制劑,配合飲食控制和運動,用於改善2型糖尿病患者的血糖控制。臨床數據顯示,西格列汀基本沒有引起低血糖的風險,無劑量滴定且沒有腸胃道反應,每日口服一次即可有效控制血糖,並可有效延緩糖尿病進展。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account